Literature DB >> 30328700

Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.

Narayanaiah Cheedarla1, Jagadish Chandrabose Sundaramurthi1, Babu Hemalatha1, Brahmaiah Anangi2, Manohar Nesakumar1, Manickam Ashokkumar1, K K Vidya Vijayan1, Srikanth Prasad Tripathy1, Soumya Swaminathan1, S Kalyanaraman Vaniambadi3, D Vadakkupattu Ramanathan1, Luke Elizabeth Hanna1.   

Abstract

Several broadly neutralizing antibodies (bNAbs) that can target HIV strains with large degrees of variability have recently been identified. However, efforts to induce synthesis of such bNAbs that can protect against HIV infection have not met with much success. Identification of specific epitopes encoded in the HIV-1 envelope (Env) that can direct the host to synthesize bNAbs remains a challenge. In a previous study, we identified 12 antiretroviral therapy-naive HIV-1-infected individuals whose plasma exhibited broad cross-clade neutralization property against different clades of HIV-1. In this study, we sequenced the full-length HIV-1 gp160 from 11 of these individuals and analyzed the sequences to identify bNAb epitopes. We identified critical residues in the viral envelopes that contribute to the formation of conformational epitopes and possibly induce the production of bNAbs, using in silico methods. We found that many of the sequences had conserved glycans at positions N160 (10/11) and N332 (9/11), which are known to be critical for the binding of PG9/PG16-like and PGT128-like bNAbs, respectively. We also observed conservation of critical glycans at positions N234 and N276 critical for the interaction with CD4 binding site bNAbs in 8/11 and 11/11 sequences, respectively. We modeled the three-dimensional structure of the 11 HIV-1 envelopes and found that though each had structural differences, the critical residues were mostly present on the surface of the Env structures. The identified critical residues are proposed as candidates for further evaluation as bNAb epitopes.

Entities:  

Keywords:  HIV-1; HIV-1 Env structure; broadly neutralizing antibodies; epitope specificity; subtype C envelope

Mesh:

Substances:

Year:  2018        PMID: 30328700      PMCID: PMC6909397          DOI: 10.1089/AID.2018.0224

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  65 in total

1.  Emergence of a unique recombinant form of HIV-1 from Manipur (India).

Authors:  Roni Sarkar; Kamalesh Sarkar; N Brajachand Singh; Y Manihar Singh; Debashis Mitra; Sekhar Chakrabarti
Journal:  J Clin Virol       Date:  2012-08-13       Impact factor: 3.168

2.  Transmission of genetically diverse strains of HIV-1 in Pune, India.

Authors:  D A Gadkari; D Moore; H W Sheppard; S S Kulkarni; S M Mehendale; R C Bollinger
Journal:  Indian J Med Res       Date:  1998-01       Impact factor: 2.375

3.  The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Authors:  Cheryl J Saunders; Ruth A McCaffrey; Irina Zharkikh; Zane Kraft; Susan E Malenbaum; Brian Burke; Cecilia Cheng-Mayer; Leonidas Stamatatos
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Authors:  Emilia Falkowska; Alejandra Ramos; Yu Feng; Tongqing Zhou; Stephanie Moquin; Laura M Walker; Xueling Wu; Michael S Seaman; Terri Wrin; Peter D Kwong; Richard T Wyatt; John R Mascola; Pascal Poignard; Dennis R Burton
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

Authors:  Joris Hemelaar; Eleanor Gouws; Peter D Ghys; Saladin Osmanov
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

6.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Authors:  Georgia D Tomaras; Nicole L Yates; Pinghuang Liu; Li Qin; Genevieve G Fouda; Leslie L Chavez; Allan C Decamp; Robert J Parks; Vicki C Ashley; Judith T Lucas; Myron Cohen; Joseph Eron; Charles B Hicks; Hua-Xin Liao; Steven G Self; Gary Landucci; Donald N Forthal; Kent J Weinhold; Brandon F Keele; Beatrice H Hahn; Michael L Greenberg; Lynn Morris; Salim S Abdool Karim; William A Blattner; David C Montefiori; George M Shaw; Alan S Perelson; Barton F Haynes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India.

Authors:  Nagadenahalli B Siddappa; Prashanta K Dash; Anita Mahadevan; Narayana Jayasuryan; Fen Hu; Bethany Dice; Randy Keefe; Kadappa S Satish; Bhuthiah Satish; Kuttan Sreekanthan; Ramdas Chatterjee; Kandala Venu; Parthasarathy Satishchandra; Vasanthapuram Ravi; Susarla K Shankar; Raj Shankarappa; Udaykumar Ranga
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Authors:  Xiaoying Shen; Robert J Parks; David C Montefiori; Jennifer L Kirchherr; Brandon F Keele; Julie M Decker; William A Blattner; Feng Gao; Kent J Weinhold; Charles B Hicks; Michael L Greenberg; Beatrice H Hahn; George M Shaw; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

9.  Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.

Authors:  Lubina Khan; Muzamil Ashraf Makhdoomi; Sanjeev Kumar; Ambili Nair; Raiees Andrabi; Brenda E Clark; Kate Auyeung; Jayanta Bhattacharya; Madhu Vajpayee; Naveet Wig; Ralph Pantophlet; Kalpana Luthra
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

10.  Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response.

Authors:  D N Shcherbakov; A Y Bakulina; L I Karpenko; A A Ilyichev
Journal:  Acta Naturae       Date:  2015 Oct-Dec       Impact factor: 1.845

View more
  1 in total

1.  A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing.

Authors:  Rohini Datta; Rohan Roy Chowdhury; Kavyashree Manjunath; Luke Elizabeth Hanna; Raghavan Varadarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-09       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.